Journal ArticleDOI
Triple pharmacological blockade of the renin-angiotensin-aldosterone system in nondiabetic CKD: an open-label crossover randomized controlled trial.
Leszek Tylicki,Przemysław Rutkowski,Marcin Renke,Wojciech Larczyński,Ewa Aleksandrowicz,Wieslawa Lysiak-Szydlowska,Bolesław Rutkowski +6 more
TLDR
Administration of an aldosterone receptor antagonist in addition to double RAAS blockade with an ACE inhibitor and ARB may slow the progression of chronic kidney disease.About:
This article is published in American Journal of Kidney Diseases.The article was published on 2008-09-01. It has received 100 citations till now. The article focuses on the topics: Blockade & Angiotensin II.read more
Citations
More filters
Journal ArticleDOI
Aldosterone: effects on the kidney and cardiovascular system
Marie Briet,Ernesto L. Schiffrin +1 more
TL;DR: Several lines of evidence support the existence of crosstalk between aldosterone and angiotensin II in vascular smooth muscle cells, and large interventional trials that test the efficacy and safety of mineralocorticoid-receptor antagonists in chronic kidney disease are needed.
Journal ArticleDOI
Aldosterone Antagonists for Preventing the Progression of Chronic Kidney Disease: A Systematic Review and Meta-analysis
TL;DR: Aldosterone antagonists reduce proteinuria in CKD patients already on ACEis and ARBs but increase the risk of hyperkalemia.
Journal ArticleDOI
Mechanisms and Treatment of CKD
TL;DR: In addition to RAS inhibitors, however, multimodal approaches including lifestyle modifications and multidrug therapy will be required in most cases to optimize control of the several risk factors for CKD and related cardiovascular morbidity.
Journal ArticleDOI
Potassium Homeostasis and Renin-Angiotensin-Aldosterone System Inhibitors
Matthew R. Weir,Mark Rolfe +1 more
TL;DR: Patients with hypertension, heart failure, or chronic kidney disease and patients with HF or CKD are at greater risk of hyperkalemia with RAAS inhibitors than those without these conditions, and electrolyte levels should be closely monitored in patients.
Journal ArticleDOI
Aldosterone antagonists for preventing the progression of chronic kidney disease.
TL;DR: Non-selective aldosterone antagonists (spironolactone) combined with ACEi or ARB (or both) significantly reduced 24-hour protein excretion and increased the risk of gynaecomastia compared to ACEi and ARB.
References
More filters
Journal ArticleDOI
Prediction of Creatinine Clearance from Serum Creatinine
Donald W. Cockcroft,M H Gault +1 more
TL;DR: A formula has been developed to predict Creatinine clearance from serum creatinine (Scr) in adult males: Ccr = (140 – age) (wt kg)/72 × Scr (mg/100ml) (15% less i).
Journal ArticleDOI
Procedures for Detecting Outlying Observations in Samples
TL;DR: In this paper, a procedure for determining statistically whether the highest observation, lowest observation, highest and lowest observations, or more of the observations in the sample are statistical outliers is given.
Book
Cross-over trials in clinical research
TL;DR: The AB/BA Design with Normal Data and other Outcomes, and Mathematical Approaches to Carry-over References: Some Basic Considerations Concerning Estimation in Clinical Trials.
Journal ArticleDOI
RETRACTED: Combination treatment of angiotensin-II receptor blocker and angiotensin-converting-enzyme inhibitor in non-diabetic renal disease (COOPERATE): a randomised controlled trial
TL;DR: Combination treatment safely retards progression of non-diabetic renal disease compared with monotherapy, however, since some patients reached the combined primary endpoint on combined treatment, further strategies for complete management of progressive nondi diabetic renal disease need to be researched.
Journal ArticleDOI
Combination treatment of angiotensin-II receptor blocker and angiotensin-converting-enzyme inhibitor in non-diabetic renal disease (COOPERATE): a randomised controlled trial☆
TL;DR: Combination treatment safely retards progression of non-diabetic renal disease compared with monotherapy, however, since some patients reached the combined primary endpoint on combined treatment, further strategies for complete management of progressivenon-di diabetic renal disease need to be researched.
Related Papers (5)
Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial
Johannes F.E. Mann,Roland E. Schmieder,Matthew J. McQueen,Leanne Dyal,Helmut Schumacher,Janice Pogue,Xingyu Wang,Aldo P. Maggioni,Andrzej Budaj,Suphachai Chaithiraphan,Kenneth Dickstein,Matyas Keltai,Kaj Metsärinne,Ali Oto,Alexander Parkhomenko,Leopoldo S. Piegas,Tage Lysbo Svendsen,Koon K. Teo,Salim Yusuf +18 more